Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Crook

Showing results (371-380 of 381) with videos related to

Pageof 39
Sort By:
Stem Cell Reports|September 13, 2023
ISSCR standards for the use of human stem cells in basic researchTenneille E Ludwig, Peter W Andrews, Ivana Barbaric, et al.
Nature Communications|October 24, 2025
Mechanobiologically-optimized non-resorbable artificial bone for patient-matched scaffold-guided bone regenerationJonathan R Clark, D S Abdullah Al Maruf, Eva Tomaskovic-Crook, et al.
Plos Medicine|January 23, 2015
Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysisCharles S Morrison, Pai-Lien Chen, Cynthia Kwok, et al.
The New England Journal of Medicine|March 9, 2022
Shorter Treatment for Nonsevere Tuberculosis in African and Indian ChildrenAnna Turkova, Genevieve H Wills, Eric Wobudeya, et al.
Stem Cell Reports|January 11, 2018
A Standard Nomenclature for Referencing and Authentication of Pluripotent Stem CellsAndreas Kurtz, Stefanie Seltmann, Amos Bairoch, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 14, 2023
Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus studyMark T Corkum, Mark K Buyyounouski, Albert J Chang, et al.
The Lancet. Infectious Diseases|May 20, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMuge Cevik, Lindsay C Thompson, Caryn Upton, et al.
Nature Communications|December 15, 2025
Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastomaGeorge L Joun, Emma G Kempe, Brianna Chen, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 25, 2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TBC D Tweed, G H Wills, A M Crook, et al.
Regenerative Medicine|February 13, 2015
Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)P W Andrews, D Baker, N Benvinisty, et al.
Pageof 39

Showing results (371-380 of 381) with videos related to

Sort By:
Pageof 39
Stem Cell Reports|September 13, 2023
ISSCR standards for the use of human stem cells in basic researchTenneille E Ludwig, Peter W Andrews, Ivana Barbaric, et al.
Nature Communications|October 24, 2025
Mechanobiologically-optimized non-resorbable artificial bone for patient-matched scaffold-guided bone regenerationJonathan R Clark, D S Abdullah Al Maruf, Eva Tomaskovic-Crook, et al.
Plos Medicine|January 23, 2015
Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysisCharles S Morrison, Pai-Lien Chen, Cynthia Kwok, et al.
The New England Journal of Medicine|March 9, 2022
Shorter Treatment for Nonsevere Tuberculosis in African and Indian ChildrenAnna Turkova, Genevieve H Wills, Eric Wobudeya, et al.
Stem Cell Reports|January 11, 2018
A Standard Nomenclature for Referencing and Authentication of Pluripotent Stem CellsAndreas Kurtz, Stefanie Seltmann, Amos Bairoch, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 14, 2023
Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus studyMark T Corkum, Mark K Buyyounouski, Albert J Chang, et al.
The Lancet. Infectious Diseases|May 20, 2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMuge Cevik, Lindsay C Thompson, Caryn Upton, et al.
Nature Communications|December 15, 2025
Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastomaGeorge L Joun, Emma G Kempe, Brianna Chen, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 25, 2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TBC D Tweed, G H Wills, A M Crook, et al.
Regenerative Medicine|February 13, 2015
Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)P W Andrews, D Baker, N Benvinisty, et al.
Pageof 39